# MO earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/MO) · [Earnings tab](https://www.lopjlb.com/stock/MO?tab=earnings)

Updated: 2026-10-05T07:55:51

Quarters analyzed: 8

## Cross-quarter narrative

Across 8 calls for MO, management tone moved from +0.00 (2024 Q3) to +0.30 (2026 Q2). Latest guidance stance: raised. Latest desk line: Altria raised FY26 EPS guidance to $5.61-$5.72 after strong H1; on! PLUS expanding nationally, cigarette volume declines moderating, smokeable OCI margins expanding.

## Latest CallCard · Q2

Altria raised FY26 EPS guidance to $5.61-$5.72 after strong H1; on! PLUS expanding nationally, cigarette volume declines moderating, smokeable OCI margins expanding.

**Guidance:** raised — Raised lower end of full year 2026 adjusted diluted EPS guidance to $5.61-$5.72 (3.5%-5.5% growth) from prior range.

**Tone:** mgmt 0.3 · Q&A pressure 0.6 · divergence 0.2

Management highlighted strong first half results, narrowed guidance, expanding smoke-free portfolio, and regulatory clarity, while acknowledging consumer pressure from inflation and gas prices.

### Demand visibility

Cigarette volume declines moderating for fourth consecutive quarter; nicotine pouch category growing rapidly; discount segment gaining share due to economic pressure; on! retail share increasing.

Domestic cigarette volumes declined 3.2% reported (4.5% adjusted) in Q2; industry volumes down 5% adjusted. Discount retail share grew 2.6 share points. Nicotine pouch category grew 8.1 share points to nearly 60% of oral category. on! retail share reached 8.6%, up 0.8 share points sequentially. Consumer pressure from elevated gas prices and inflation exceeding wage growth driving trade-down.

### Margins / costs

Smokeable OCI margins expanded to 64.8% in Q2; Oral tobacco margins strong at 66.7%; price realization 4.5% driven by Marlboro net pricing partially offset by Basic mix; strategic investments in on! PLUS introductory offers pressured Oral segment OCI.

Smokeable adjusted OCI grew 2.4% to $3B in Q2, margins 64.8%. Oral adjusted OCI decreased 8% in Q2 due to tough prior year comps and on! PLUS trial investments, margins 66.7%. Marlboro retail price up ~7% year-over-year. Basic volume growth offsetting Marlboro mix.

### Capital allocation

Returned $3.9B to shareholders in H1 ($3.6B dividends, $335M buybacks); $665M remaining under buyback program expiring year-end; debt-to-EBITDA 1.9x, target ~2x; committed to dividend, buybacks, debt management, and M&A for smoke-free/adjacency vision.

## Quarter one-liners

- **2026 Q2:** Altria raised FY26 EPS guidance to $5.61-$5.72 after strong H1; on! PLUS expanding nationally, cigarette volume declines moderating, smokeable OCI margins expanding.
- **2026 Q1:** Altria posted a strong Q1 2026 with EPS up 7.3%, premium Marlboro share modestly higher and on! PLUS expanding to 100k stores, while reaffirming full‑year guidance amid macro‑economic uncertainty.
- **2025 Q4:** Altria posted solid 2025 results, grew adjusted EPS 4.4%, expanded margins, advanced smoke‑free products, but flagged illicit e‑vapor and FDA timing as headwinds while guiding 2026 EPS $5.56‑$5.72.
- **2025 Q3:** Altria posted modest earnings growth, expanded its on! PLUS nicotine‑pouch launch and highlighted regulatory progress, while noting competitive promotions, litigation and FDA timing risks.
- **2025 Q2:** Altria raised the lower end of its 2025 EPS guidance, highlighted strong on! nicotine‑pouch growth and oral‑tobacco margins, while noting regulatory, illicit‑vapor and tariff headwinds.
- **2025 Q1:** Altria Q1: ON! nicotine pouches grow 18% volume, 8.8% oral share; NJOY ACE exits after ITC orders triggering $873M impairment; smokeable OCI up 2.7% on 10.8% price realization; guidance maintained at $5.30-$5.45 EPS; illicit e-vapor >60% of category, tariff impact limited so far.
- **2024 Q4:** Altria posted modest earnings growth and smoke‑free gains, but warns that illicit e‑vapor products and regulatory uncertainty cloud its 2028 smoke‑free targets.
- **2024 Q3:** —

## Theme arcs

- **Management tone** (improving): Δ mgmt=+0.30

## Fear persistence

- **regulatory** [recurring]: 2024 Q4, 2025 Q2, 2025 Q4, 2025 Q4
- **economic** [resolved]: 2024 Q4
- **legal** [resolved]: 2024 Q4
- **tariff** [resolved]: 2024 Q4
- **market** [resolved]: 2024 Q4
- **supply chain** [recurring]: 2024 Q4, 2025 Q2
- **policy** [resolved]: 2024 Q4
- **illicit e-vapor market dominance** [resolved]: 2025 Q1
- **fda/ctp enforcement uncertainty** [resolved]: 2025 Q1
- **itc exclusion order impact** [resolved]: 2025 Q1

## Guidance path

2024 Q3:vague → 2024 Q4:maintained → 2025 Q1:maintained → 2025 Q2:raised → 2025 Q3:vague → 2025 Q4:maintained → 2026 Q1:maintained → 2026 Q2:raised

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/MO`